New Publications Show Promise of Improved Artificial Lung Devices

3 August 2015 Press Release, Recent News

Technology developed at the University of Pittsburgh and licensed by ALung enhances the performance of artificial lung devices, paving the way for the development of less invasive respiratory support systems.

Pittsburgh, PA (August 3, 2015) – ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, today announced the publication of new data by University of Pittsburgh researchers on two groundbreaking technologies it has previously licensed from the University. The new technologies, which help enhance the performance of artificial lung devices, were developed by Dr. William Federspiel, Professor of Bioengineering at the University of Pittsburgh, and his team in the Medical Devices Laboratory of the McGowan Institute for Regenerative Medicine. Dr. Federspiel is also a co-founder of ALung Technologies.

Artificial lung devices are used to support patients with lung failure. They work by passing a patient’s blood over an artificial membrane which removes carbon dioxide and delivers oxygen to the blood, independently of the native lung. While today’s artificial lung technology is very good, a clinical need still exists for more efficient, minimally invasive devices. The new techniques developed by Dr. Federspiel use a combination of two biochemical approaches that work synergistically to more than double the rate of carbon dioxide removal across the artificial lung membrane. The work of Dr. Federspiel’s team was recently published in the journals Acta Biomaterialia and the Journal of Material Science: Materials in Medicine, designated in the latter as an “Editor’s Choice” paper.

ALung’s license agreement with the University Pittsburgh for this new technology includes two pending patent applications. “These novel technologies fit nicely within our broader intellectual property portfolio of methods for enhancing gas exchange,” said Peter DeComo, ALung Chairman and CEO. “The continued refinement of these techniques, as highlighted in the new publications, help pave the way for the future development of more effective artificial lung devices for the millions of patients with acute and chronic lung failure. We offer Dr. Federspiel and his team our congratulations on their most recent publications.”

ALung’s Hemolung Respiratory Assist System, a minimally invasive extracorporeal CO2 removal system for treating patients with acute respiratory failure, also incorporates technology licensed from the University of Pittsburgh.

About ALung Technologies

ALung Technologies, Inc. is a privately-held Pittsburgh-based developer and manufacturer of innovative lung assist devices. Founded in 1997 as a spin-out of the University of Pittsburgh, ALung has developed the Hemolung RAS as a dialysis-like alternative or supplement to mechanical ventilation. ALung is backed by individual investors and venture firms including Allos Ventures, Birchmere Ventures and West Capital Advisors, LLC.

For more information about ALung and the Hemolung RAS, visit www.alung.com.

This press release may contain forward-looking statements, which, if not based on historical facts, involve current assumptions and forecasts as well as risks and uncertainties. Our actual results may differ materially from the results or events stated in the forward-looking statements, including, but not limited to, certain events not within the Company’s control. Events that could cause results to differ include failure to meet ongoing developmental and manufacturing timelines, changing GMP requirements, the need for additional capital requirements, risks associated with regulatory approval processes, adverse changes to reimbursement for the Company’s products/services, and delays with respect to market acceptance of new products/services and technologies. Other risks may be detailed from time to time, but the Company does not attempt to revise or update its forward-looking statements even if future experience or changes make it evident that any projected events or results expressed or implied therein will not be realized.

###

Media Contact:

Scott Morley
Vice President of Marketing
ALung Technologies
+1-412-697-3370 ext. 208
smorley@alung.com

Additional Links:

D.T. Arazawa, J.D. Kimmel, M.C. Finn, W.J. Federspiel, Acidic sweep gas with carbonic anhydrase coated hollow fiber membranes synergistically accelerates CO2 removal from blood, Acta Biomaterialia, Available online 6 July 2015.

D.T. Arazawa, J.D. Kimmel, W.J. Federspiel. Kinetics of CO2 exchange with carbonic anhydrase immobilized on fiber membranes in artificial lungs, Journal of Materials Science: Materials in Medicine June 2015, 26:193.

View this release on Business Wire